A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 35, Issue 2, 2017, Pages 39.e1-39.e7

  Donin, Nicholas M ^a   Chamie, Karim ^a   Lenis, Andrew T ^a   Pantuck, Allan J ^a   Reddy, Madhu ^b   Kivlin, Dana ^b   Holldack, Johanna ^c   Pozzi, Rafaella ^c   Hakim, Gil ^g   Karsh, Lawrence I ^d   Lamm, Donald L ^e   Belkoff, Laurence H ^b   Belldegrun, Arie S ^a   Holden, Stuart ^a   Shore, Neal ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^c Telormedix SA   (Switzerland)

^d Urology Center of Colorado   (United States)

^e BCG Oncology   (United States)

^f Carolina Urologic Research Center   (United States)

^g UroGen Pharma Ltd   (Israel)

Author keywords

Administrations, intravesical drug; Carcinoma in situ; Imiquimod; Immunotherapy; Urinary bladder neoplasms

Indexed keywords

BCG VACCINE; IMIQUIMOD; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; VALRUBICIN; VASCULOTROPIN; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYTOKINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; BREAST DISEASE; CARCINOMA IN SITU; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; FATIGUE; FEMALE; HEMATURIA; HUMAN; MALE; MULTICENTER STUDY; NON MUSCLE INVASIVE BLADDER CANCER; OPEN STUDY; PENIS DISEASE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SIDE EFFECT; TREATMENT RESPONSE; URINARY TRACT INFECTION; URINARY URGENCY; URINE CYTOLOGY; URINE RETENTION; BLADDER TUMOR; CHEMICALLY INDUCED; CLINICAL TRIAL; INTRAVESICAL DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME; URINE; VERY ELDERLY;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA IN SITU; CYTOKINES; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84994059878     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2016.09.006     Document Type: Article

References (28)

1. [1] Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
2. [2] Kirkali, Z., Chan, T., Manoharan, M., Algaba, F., Busch, C., Cheng, L., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66:6 Suppl 1 (2005), S4–S34.
3. [3] American Urological Association. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis): 2007 update. Available from: http://ww.auanet.org/education/guidelines/bladder-cancer.cfm [cited 22.01.16].
4. [4] Sylvester, R.J., van der Meijden, A.P.M., Witjes, J.A., Kurth, K., Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174 (2005), 86–91 [discussion 91–2].
5. [5] Jakse, G., Hall, R., Bono, A., Höltl, W., Carpentier, P., Spaander, J.P., et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol 40 (2001), 144–150.
6. [6] Takenaka, A., Yamada, Y., Miyake, H., Hara, I., Fujisawa, M., Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder. Int J Urol 15 (2008), 309–313.
7. [7] Zlotta, A.R., Fleshner, N.E., Jewett, M.A., The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J 3:6 Suppl 4 (2009), S199–S205.
8. [8] Steinberg, G., Bahnson, R., Brosman, S., Middleton, R., Wajsman, Z., Wehle, M., Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. the Valrubicin Study Group. J Urol 163 (2000), 761–767.
9. [9] Mancuso, G., Gambuzza, M., Midiri, A., Biondo, C., Papasergi, S., Akira, S., et al. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol 10 (2009), 587–594.
10. [10] Schon, M., Schon, M.P., The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr Med Chem 14 (2007), 681–687.
11. [11] Smith, E.B., Schwartz, M., Kawamoto, H., You, X., Hwang, D., Liu, H., et al. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J Urol 177 (2007), 2347–2351.
12. [12] Sidky, Y.A., Borden, E.C., Weeks, C.E., Reiter, M.J., Hatcher, J.F., Bryan, G.T., Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res 52 (1992), 3528–3533.
13. [13] Hayashi, T., Crain, B., Corr, M., Chan, M., Cottam, H.B., Maj, R., et al. Intravesical toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer. Int J Urol 17 (2010), 483–490.
14. [14] Falke, J., Lammers, R.J.M., Arentsen, H.C., Ravic, M., Pozzi, R., Cornel, E.B., et al. Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer. J Urol 189 (2013), 2077–2082.
15. [15] Arentsen, H.C., Hulsbergen-Van de Kaa, C.A., Jansen, C.F.J., Maj, R., Leoni, L.M., Oosterwijk, E., et al. Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs. BJU Int 108 (2011), 1210–1214.
16. [16] Di Lorenzo, G., Perdonà, S., Damiano, R., Faiella, A., Cantiello, F., Pignata, S., et al. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 116 (2010), 1893–1900.
17. [17] McKiernan, J.M., Masson, P., Murphy, A.M., Goetzl, M., Olsson, C.A., Petrylak, D.P., et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24 (2006), 3075–3080.
18. [18] Akira, S., Uematsu, S., Takeuchi, O., Pathogen recognition and innate immunity. Cell 124 (2006), 783–801.
19. [19] LaRue, H., Ayari, C., Bergeron, A., Fradet, Y., Toll-like receptors in urothelial cells—targets for cancer immunotherapy. Nat Rev Urol 10 (2013), 537–545.
20. [20] Redelman-Sidi, G., Glickman, M.S., Bochner, B.H., The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat Rev Urol 11 (2014), 153–162.
21. [21] Thalmann, G.N., Sermier, A., Rentsch, C., Möhrle, K., Cecchini, M.G., Studer, U.E., Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 164 (2000), 2129–2133.
22. [22] Lamm, D.L., van der Meijden, P.M., Morales, A., Brosman, S.A., Catalona, W.J., Herr, H.W., et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147 (1992), 596–600.
23. [23] Shang, P.F., Kwong, J., Wang, Z.P., Tian, J., Jiang, L., Yang, K., et al. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev, 5, 2011, CD006885.
24. [24] Chamie, K., Saigal, C.S., Lai, J., Hanley, J.M., Setodji, C.M., Konety, B.R., et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 117 (2011), 5392–5401.
25. [25] Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 (2013), 214–218.
26. [26] Powles, T., Eder, J.P., Fine, G.D., Braiteh, F.S., Loriot, Y., Cruz, C., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
27. [27] Plunkett, W., Huang, P., Xu, Y.Z., Heinemann, V., Grunewald, R., Gandhi, V., Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:4 Suppl 11 (1995), S3–S10.
28. [28] Verweij, J., Pinedo, H.M., Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1 (1990), 5–14.